SkyQuest Technology Group has recently published a comprehensive Genome Editing Market report, offering a detailed analysis of the product landscape and industry scope while providing insights into the market outlook and future trends from 2025 to 2032. The Genome Editing Market is characterized by moderate merger and acquisition activity by many industry players. This is due to several factors including the desire to gain a competitive advantage in the industry. For example, in January 2024, Ginkgo Bioworks launched market that it has acquired Proof Diagnostics, expanding Ginkgo’s portfolio of products into medical genetics repair tools.
Genome Editing Market size was valued at USD 5.92 billion in 2023 and is poised to grow from USD 6.87 billion in 2024 to USD 22.69 billion by 2032, growing at a CAGR of 16.1% during the forecast period (2025-2032).
Large players are adopting this strategy to increase their productivity and marketability and improve their product availability in various geographies. In addition, specialized strategies to raise awareness among students and increase educational materials are expected to boost the genome editing market. For example, in March 2024 Carolina Biological Supply Company and Christianacare Gene Editing Institute worked 9 to 12 Developed exclusive CRISPR in Box educational kit for upper grades and university, offering hands-on instruction in CRISPR techniques.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/genome-editing-market
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Genome Editing Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Genome Editing Market is segmented by Technology, Delivery Method, Application, Mode, End-use and region.
Based on Technology, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease and Others.
Based on Delivery Method, the market is segmented into Ex-vivo and In-vivo.
Based on Application, the market is segmented into Genetic Engineering, Cell line engineering, Animal genetic engineering, Plant genetic engineering, Others, Clinical Applications, Diagnostics and Therapy Development.
Based on Mode, the market is segmented into Contract and In-house.
Based on End-use, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes and Contract research organizations.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Genome Editing Market – Regional Analysis:
North America is dominated the genome editing market, accounting for 47.81% in 2023 due to rising investments in R&D of gene editing technologies. Several biotechnologies and the pharmaceutical companies operating in the genome editing technology are estimated to remain dominant over the forecast period. Availability of strong research infrastructure, rise in genetically modified crops, high genetic diseases inherited diseases are common.
Asia Pacific is expected to witness fastest growth at 18.75% CAGR between 2024 and 2030. Also attracting investment and finance from domestic companies providing gene editing products and services. For example, in April 2021, GeneScript launched a Research-Grade Lentiviral Vector Packaging Service for drug discovery, cell line manufacturing and gene editing.
Top Market Players in Genome Editing Market are:
Merck KGaA (Germany)
Cibus Inc (US)
Recombinetics (US)
Sangamo Therapeutics (US)
Editas Medicine (US)
Precision BioSciences (US)
CRISPR Therapeutics (Switzerland)
Intellia Therapeutics, Inc (US)
Caribou Biosciences, Inc. (US)
Cellectis S.A (France)
AstraZeneca (UK)
Takara Bio Inc. (Japan)
Danaher Corporation (US)
Transposagen Biopharmaceuticals, Inc. (US)
Genscript Biotech Corp (China)
New England Biolabs (US)
OriGene Technologies, Inc. (US)
Lonza (Switzerland)
Thermo Fisher Scientific Inc. (US)
Genome Editing Market Recent Developments:
In January 2024, Danaher Corporation partnered with the Innovative Genomics Institute (IGI).
In November 2023, Selectis signed a collaboration agreement with AstraZeneca to accelerate the development of advanced therapies in oncology and immunology.
In July 2023, Sangamo Therapeutics partnered with Chroma Medicine to develop epigenetic drugs using Sangamo’s zinc finger proteins (ZFPs).
You may Also Like
https://issuu.com/skyquest-technology/docs/electrolyzer_market_powering_the_green_hydrogen_r
https://issuu.com/skyquest-technology/docs/green_ammonia_market_size_share_and_growth_analy
Forward-Looking Insights
The Genome Editing Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
